MAPT and Alzheimer disease: Current clinical AD risk assessment relies on extensive cognitive and behavioral testing19 and positron emission tomography (PET)/cerebrospinal fluid (CSF) biomarkers of amyloid beta (Aβ) and tau; however, they have not been widely adopted in clinical settings due to cost and limited availability.